LON:IMM ImmuPharma (IMM) Share Price, News & Analysis GBX 4.33 +0.03 (+0.70%) As of 06/1/2026 12:14 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About ImmuPharma Stock (LON:IMM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ImmuPharma alerts:Sign Up Key Stats Today's Range 4.33▼ 4.9050-Day Range 4▼ 5.4652-Week Range 1.39▼ 19.40Volume1.17 million shsAverage Volume2.94 million shsMarket Capitalization£27.02 millionP/E RatioN/ADividend Yield0.77%Price TargetN/AConsensus RatingN/A Company Overview ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. Read More Receive IMM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMM Stock News HeadlinesImmuPharma focused on securing P140 licensing deal in 2026May 28, 2026 | uk.finance.yahoo.comImmuPharma launches regulatory push for Kapiglucagon diabetes drugMay 6, 2026 | uk.finance.yahoo.com"You'll own nothing and be happy" (it's not a theory anymore)Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.June 2 at 1:00 AM | Decentralized Masters (Ad)ImmuPharma PLCApril 24, 2026 | marketwatch.comImmuPharma: P140 partnering discussions continue; overwhelming backing for investment roundApril 9, 2026 | uk.finance.yahoo.comImmuPharma shares rise on patent milestone and "supportive" studyMarch 28, 2026 | lse.co.ukImmuPharma advances P140 partnering talks as patent progress and new study data strengthen programmeMarch 28, 2026 | uk.finance.yahoo.comImmuPharma shares surge 20% as P140 partnering talks advanceMarch 28, 2026 | uk.finance.yahoo.comSee More Headlines IMM Stock Analysis - Frequently Asked Questions How have IMM shares performed this year? ImmuPharma's stock was trading at GBX 6.20 at the beginning of the year. Since then, IMM shares have decreased by 30.2% and is now trading at GBX 4.33. How were ImmuPharma's earnings last quarter? ImmuPharma plc (LON:IMM) released its quarterly earnings results on Wednesday, May, 27th. The company reported ($0.37) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative trailing twelve-month return on equity of 1,397.44%. How do I buy shares of ImmuPharma? Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of ImmuPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuPharma investors own include Castleton Technology (CTP), 4D pharma (DDDD), Thor Energy (THR), Aminex (AEX) and GSK (GSK). Company Calendar Last Earnings5/27/2026Today6/02/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:IMM CIKN/A Webwww.immupharma.org Phone+44-20-71524080FaxN/AEmployees13Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£2.51 million Net Margins3,519.56% Pretax MarginN/A Return on Equity-1,397.44% Return on Assets-43.00% Debt Debt-to-Equity RatioN/A Current Ratio1.52 Quick Ratio1.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 0.21 per share Price / Cash Flow20.50 Book ValueGBX 0.65 per share Price / Book6.71Miscellaneous Outstanding Shares623,911,000Free FloatN/AMarket Cap£27.02 million OptionableNot Optionable Beta2.98 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (LON:IMM) was last updated on 6/2/2026 by MarketBeat.com Staff. From Our PartnersThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...Traders Agency | SponsoredGold hit $4,500 - but these miners haven't caught up yet$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredRevealed: The Best Kept Secrets On Wall StreetTom Busby, founder of the Diversified Trading Institute, is giving away his 'Little Black Book' - a collection...DTI Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
